EUCTR2005-002909-23-SE进行中（未招募）不适用
ong-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA core studies. - GROWTH96
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 2,420
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •patients who have completed participation in one of the core studies (e.g. WA17824, WA18062, WA18063, and WP18663) in adult rheumatoid arthritis.
- •inadequate response to a stable dose of MTX or other allowable Disease Modifying Anti-Rheumatic Drug (DMARD).
- •patients of reproductive potential must be using reliable methods of contraception.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1711
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 357
排除标准
- •treatment with any investigational agent since the last administration of study drug in core studies.
- •treatment with iv gamma globulin, plasmapheresis or prosorba column since the last administration of study drug in core studies.
- •treatment with an anti-tumor necrosis factor agent or anti-IL-1 agent, or a T-cell costimulation modulator or any biologic since the last administration of study drug in the core studies.
研究者
相似试验
进行中（未招募）
不适用
ong-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in WA 17822MedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2005-002423-13-ITF.Hoffmann La Roche Ltd630
进行中（未招募）
不适用
ong-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA core studies.MedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2005-002909-23-ITF. Hoffmann - La Roche Ltd2,420
进行中（未招募）
不适用
ong-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA core studies.Rheumatoid arthritisEUCTR2005-002909-23-DEF Hoffmann-La Roche AG2,420
进行中（未招募）
1 期
ong-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA core studies. - NARheumatoid arthritisEUCTR2005-002909-23-GBF Hoffmann La-Roche AG2,420
进行中（未招募）
不适用
ong-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA core studies.Rheumatoid arthritisEUCTR2005-002909-23-NOF Hoffmann La-Roche AG2,420